Abnova Taiwan Corp - Asset Resilience Ratio

Latest as of December 2025: 0.07%

Abnova Taiwan Corp (4133) has an Asset Resilience Ratio of 0.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$880.00K
≈ $27.72K USD Cash + Short-term Investments

Total Assets

NT$1.33 Billion
≈ $41.82 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Abnova Taiwan Corp's Asset Resilience Ratio has changed over time. Check Abnova Taiwan Corp (4133) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Abnova Taiwan Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abnova Taiwan Corp market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$880.00K 0.07%
Total Liquid Assets NT$880.00K 0.07%

Asset Resilience Insights

  • Limited Liquidity: Abnova Taiwan Corp maintains only 0.07% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Abnova Taiwan Corp Industry Peers by Asset Resilience Ratio

Compare Abnova Taiwan Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
Biotechnology 47.01%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Beijing Hotgen Biotech Co Ltd
SHG:688068
Biotechnology 20.87%

Annual Asset Resilience Ratio for Abnova Taiwan Corp (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Abnova Taiwan Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.07% NT$880.00K
≈ $27.72K
NT$1.33 Billion
≈ $41.82 Million
+0.00pp
2022-12-31 0.06% NT$849.00K
≈ $26.75K
NT$1.37 Billion
≈ $43.31 Million
+0.02pp
2021-12-31 0.04% NT$545.00K
≈ $17.17K
NT$1.28 Billion
≈ $40.42 Million
+0.00pp
2020-12-31 0.04% NT$543.00K
≈ $17.11K
NT$1.29 Billion
≈ $40.79 Million
0.00pp
2019-12-31 0.04% NT$540.00K
≈ $17.01K
NT$1.26 Billion
≈ $39.82 Million
+0.00pp
2018-12-31 0.04% NT$537.00K
≈ $16.92K
NT$1.29 Billion
≈ $40.80 Million
+0.00pp
2017-12-31 0.04% NT$533.00K
≈ $16.79K
NT$1.30 Billion
≈ $41.08 Million
-5.50pp
2016-12-31 5.54% NT$69.11 Million
≈ $2.18 Million
NT$1.25 Billion
≈ $39.33 Million
-10.15pp
2015-12-31 15.69% NT$195.97 Million
≈ $6.17 Million
NT$1.25 Billion
≈ $39.35 Million
+15.65pp
2014-12-31 0.04% NT$522.00K
≈ $16.45K
NT$1.31 Billion
≈ $41.21 Million
0.00pp
2013-12-31 0.04% NT$517.00K
≈ $16.29K
NT$1.29 Billion
≈ $40.49 Million
+0.00pp
2012-12-31 0.04% NT$513.00K
≈ $16.16K
NT$1.29 Billion
≈ $40.71 Million
+0.00pp
2011-12-31 0.04% NT$508.00K
≈ $16.00K
NT$1.36 Billion
≈ $42.70 Million
0.00pp
2010-12-31 0.04% NT$504.00K
≈ $15.88K
NT$1.33 Billion
≈ $42.03 Million
-1.09pp
2009-12-31 1.13% NT$14.72 Million
≈ $463.73K
NT$1.31 Billion
≈ $41.13 Million
-0.07pp
2008-12-31 1.20% NT$10.26 Million
≈ $323.21K
NT$857.02 Million
≈ $27.00 Million
--
pp = percentage points

About Abnova Taiwan Corp

TW:4133 Taiwan Biotechnology
Market Cap
$40.16 Million
NT$1.27 Billion TWD
Market Cap Rank
#22667 Global
#1408 in Taiwan
Share Price
NT$21.05
Change (1 day)
+0.72%
52-Week Range
NT$20.15 - NT$29.00
All Time High
NT$149.53
About

Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more